本文選題：消癭瘤方　切入點：甲狀腺腫瘤　出處：《河北醫(yī)科大學》2017年碩士論文

【摘要】：目的:近年來甲狀腺腫瘤的發(fā)病率逐漸增高,越來越多的甲狀腺腫瘤患者愿意嘗試安全、有效而無毒副作用的中藥。本研究通過觀察自擬消癭瘤方對甲狀腺腫瘤的治療,并與單純口服小金丸對照1組和單純口服無碘鹽對照2組進行比較,評估其對縮小腫物大小,改善臨床療效,調節(jié)甲狀腺激素水平,增強免疫功能以及安全性等方面的作用。方法:本研究入選患者為門診或體檢病例,經超聲、化驗及病理細胞學確診為結節(jié)性甲狀腺腫或甲狀腺癌,共計100例,治療組40例患者,采用自擬消癭瘤方,每周保證服用6付中藥,日1劑;對照1組30例患者,服用小金丸每次1.8g,每日2次;對照2組30例患者,改用無碘鹽,不服用任何藥物。以上三組均治療6個月后評價臨床療效。結果:1治療后,腫物改善方面,治療組痊愈5例,顯效12例,有效13例,有效率為75%;對照1組痊愈3例,顯效8例,有效10例,有效率為70%;對照2組顯效1例,有效3例,其他均無效,有效率僅為13.3%。治療組與對照1組比較P0.05,統(tǒng)計學無差異;與對照2組比較P0.01,統(tǒng)計學有顯著性差異。2甲狀腺功能方面,治療組中患者的促甲狀腺激素水平下降明顯,有統(tǒng)計學差異P0.05,對照1組中患者的促甲狀腺激素水平下降,有統(tǒng)計學差異P0.05,對照2組中患者的游離T4水平明顯增長,統(tǒng)計學有差異P0.05;治療組與對照1組比較,促甲狀腺激素水平有統(tǒng)計學差異P0.05;與對照2組比較,各項均有統(tǒng)計學差異P0.05。3免疫功能方面,治療組中CD3、CD4和CD8陽性T細胞增長顯著,均有統(tǒng)計學差異P0.05,對照1組中CD4、CD8明顯增長,有統(tǒng)計學差異P0.05,對照2組各項變化不大均沒有統(tǒng)計學差異P0.05;治療組與對照1組比較,CD3、CD4及NK均有統(tǒng)計學差異P0.05;與對照2組比較,各項均有統(tǒng)計學差異P0.05。4安全性方面,血常規(guī)中血小板和血紅蛋白均有統(tǒng)計學差異P0.05,肝腎功能中的血清學指標均在正常范圍之內,且治療前后變化較小,這就說明對肝腎損傷較小,并且在治療組未發(fā)現不良反應情況的發(fā)生。結論:自擬消癭瘤方對甲狀腺腫瘤有良好的治療作用,不僅可以有效縮小腫物大小,改善臨床癥狀,調節(jié)甲狀腺功能,同時具有較高的安全性,避免過敏等不良反應的發(fā)生,尤其在增強患者免疫功能方面,具有更加突出的優(yōu)勢,值得臨床推廣使用。
[Abstract]:Objective: in recent years, the incidence of thyroid neoplasms has gradually increased, and more and more patients of thyroid tumors are willing to try Chinese medicine which is safe, effective and without toxic side effects. Compared with the control group 1 and the control group 2 of oral iodized salt alone, the effect of Xiaojin pill on reducing the size of tumor, improving the clinical efficacy and regulating the thyroid hormone level were evaluated. Methods: in this study, 100 patients were diagnosed as nodular goiter or thyroid carcinoma by ultrasound, laboratory and pathological cytology. In the treatment group, 40 patients were treated with self-made Xiaoyingliang recipe, which was guaranteed to take 6 sets of traditional Chinese medicine once a day, 30 patients in the control group took 1.8 g Xiaojin pills twice a day, 30 patients in the control group were treated with iodized salt, and 30 patients in the control group were treated with iodized salt. No drugs were taken. The clinical efficacy was evaluated after 6 months of treatment in the above three groups. Results in the treatment group, 5 cases were cured, 12 cases were effective, 13 cases were effective, and the effective rate was 75% in the control group 1, 3 cases were cured and 8 cases had remarkable effect. The effective rate was 70% in 10 cases, 1 case in the control group, 3 cases in the control group, none in other cases, and the effective rate was only 13.3.There was no statistical difference between the treatment group and the control group (P 0.05). Compared with the control group (P0.01), there was a significant difference in thyroid function between the two groups. 2. The level of thyrotropin in the treatment group was significantly lower than that in the control group (P 0.05), and the thyroid stimulating hormone level in the control group 1 was lower than that in the control group. There was a significant difference (P0.05) in the level of free T4 between the control group and the control group (P0.05), the level of thyrotropin in the treatment group was significantly higher than that in the control group (P0.05), and the level of thyrotropin in the treatment group was significantly higher than that in the control group (P0.05). There were significant differences in immunological function between the two groups (P0.05.3). In the treatment group, CD4 and CD8 positive T cells increased significantly (P 0.05), and CD4 and CD8 increased significantly in the control group 1. There was significant difference between the two groups (P0.05), the difference between the treatment group and the control group (P0.05), the difference between the treatment group and the control group (P0.05), the difference between the treatment group and the control group (P0.05.4), the difference between the treatment group and the control group (P0.05.4), the difference between the two groups was not significant (P0.05). There were significant differences in platelet and hemoglobin in blood routine (P 0.05), serological indexes in liver and kidney function were within normal range, and the changes were small before and after treatment, which indicated that the damage to liver and kidney was less. In the treatment group, no adverse reactions were found. Conclusion: the self-made Xiao-gall tumor prescription has a good therapeutic effect on thyroid neoplasms, which can not only effectively reduce the size of the tumor, improve clinical symptoms, and regulate the thyroid function, but also can effectively reduce the size of the tumor, improve the clinical symptoms, and regulate the thyroid function. At the same time, it has higher safety, avoid the occurrence of adverse reactions such as allergies, especially in enhancing the immune function of patients with more prominent advantages, worthy of clinical use.
【學位授予單位】：河北醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R273

【參考文獻】

相關期刊論文 前10條

1 王曉濤;楊春偉;盧偉勝;趙永魁;劉洋;張國志;;血清促甲狀腺激素與甲狀腺腫瘤的關系[J];中國煤炭工業(yè)醫(yī)學雜志;2016年12期

2 景璽潤;;中醫(yī)藥治療甲狀腺癌研究近況[J];湖南中醫(yī)雜志;2016年10期

3 陳旭馮;許斌;;癭病的病因病機及治療原則初探[J];湖南中醫(yī)雜志;2015年12期

4 鄭東京;許鑫;鄭偉達;;名老中醫(yī)鄭偉達治療甲狀腺癌經驗探析[J];中醫(yī)臨床研究;2015年21期

5 張彩芬;鞏建萍;賈思躍;劉建勇;;小金丸治療甲狀腺結節(jié)126例[J];中國藥業(yè);2015年12期

6 王美花;;甲狀腺癌的診斷與治療[J];社區(qū)醫(yī)學雜志;2015年03期

7 趙許杰;閆雪生;;中藥治療甲狀腺瘤的研究進展[J];中國醫(yī)藥科學;2013年14期

8 竇景云;于俊生;;夏枯草藥理作用及臨床應用研究進展[J];現代醫(yī)藥衛(wèi)生;2013年07期

9 徐軍妹;徐輝雄;張一峰;劉暢;何勇;劉媛媛;郭樂杭;劉琳娜;;甲狀腺多發(fā)結節(jié)中偶發(fā)癌的檢出:聲脈沖輻射力彈性成像的應用價值[J];中華臨床醫(yī)師雜志(電子版);2012年24期

10 芮毅軍;;小金丸聯合甲狀腺素片治療甲狀腺良性結節(jié)的臨床應用[J];臨床醫(yī)學;2012年07期

相關博士學位論文 前1條

1 吳淑瓊;活血消癭方治療結節(jié)性甲狀腺腫的臨床療效及其作用機制研究[D];湖北中醫(yī)藥大學;2010年

，

本文編號：1675149